Abstract:Phosphatase and TENsin homolog deleted on chromosome 10 (PTEN) is a tumor suppressor gene located at chromosome 10q23.31, encoding for a 403-amino acid protein that possesses both lipid and protein phosphatase activities. The main function of PTEN is to block the PI3K pathway by dephosphorylating phosphatidylinositol (PI) 3,4,5-triphosphate to PI-4,5-bisphosphate thus counteracting PI3K function. PTEN inactivation is a frequent event in many cancer types and can occur through various genetic alterations including point mutations, large chromosomal deletions, and epigenetic mechanisms. In colorectal cancer (CRC) PTEN is altered through mixed genetic/epigenetic mechanisms (typically: mutations and promoter hypermethylation or 10q23 LOH and promoter hypermethylation), which lead to the biallelic inactivation of the protein in 20-30% of cases. The role of PTEN as a prognostic and predictive factor in CRC has been addressed by relatively few works. This review is focused on the report and on the discussion of the studies investigating these aspects. Overall, at the moment, there are conflicting results and, therefore it has not been clarified whether PTEN might play a prognostic role in CRC. The same is valid also for the predictive role, leading to the fact that PTEN evaluation cannot be used in routinely diagnosis for the early identification of patients who might be addressed to the treatment with EGFR-targeted therapies, at odds with other genetic alterations belonging to EGFR-downstream pathways. The reason of discordant results may be attributable to several issues: (1) the size of the analyzed cohort, (2) patients inclusion criteria, (3) the methods of assessing PTEN alteration. In particular, there are no standardized methods to evaluate this marker, especially for immunohistochemistry, a technique suffering of intra and inter-observer variability due to the semi-quantitative character of such an analysis. In conclusion, much work, especially in large and homogeneous cohorts of cases from different laboratories, has to be done before the establishment of PTEN as prognostic or predictive marker in CRC.

The functions and regulation of the PTEN tumour suppressor: new modes and prospects

The regulation of PTEN: Novel insights into functions as cancer biomarkers and therapeutic targets

Regulation of the tumor suppressor PTEN by natural anticancer compounds

PTEN/PTENP1: ‘Regulating the regulator of RTK-dependent PI3K/Akt signalling’, new targets for cancer therapy

Decoding PTEN: from biological functions to signaling pathways in tumors

Regulating tumor suppressor genes: post-translational modifications

The complexity of PTEN: mutation, marker and potential target for therapeutic intervention

The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer

Prognostic and Predictive Implications of PTEN in Breast Cancer: Unfulfilled Promises but Intriguing Perspectives

PTENless means more.

The functions of tumor suppressor PTEN in innate and adaptive immunity

PTEN regulation by Akt-EGR1-ARF-PTEN axis.

Targeting PTEN Regulation by Post Translational Modifications

Functions and Regulation of the PTEN Gene in Colorectal Cancer

The PTEN–PI3K pathway: of feedbacks and cross-talks

PTENε Suppresses Tumor Metastasis Through Regulation of Filopodia Formation.

PTENα functions as an immune suppressor and promotes immune resistance in PTEN-mutant cancer

PTEN Tumor Suppressor Regulates P53 Protein Levels and Activity Through Phosphatase-Dependent and -Independent Mechanisms

Pten In Regulating Hematopoiesis And Leukemogenesis

Abstract LB-24: C-terminal PTEN is Essential for Maintenance of Genomic Stability and Tumor Suppression

PTEN, a General Negative Regulator of Cyclin D Expression